No Data
Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference
PHILADELPHIA, June 05, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced
Passage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship Award
PHILADELPHIA, May 21, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases
All You Need to Know About Passage Bio (PASG) Rating Upgrade to Buy
Passage Bio Is Maintained at Buy by Canaccord Genuity
Passage Bio Is Maintained at Buy by Canaccord Genuity
Express News | Canaccord Genuity Maintains Buy on Passage Bio, Lowers Price Target to $13
Optimistic Outlook for Passage Bio Amid Clinical and Financial Progress: Maintains Buy Rating
Kevin Matte : seem next level around 1.6 or so ^^